Perceptive Advisors’s Celldex Therapeutics CLDX Stock Holding History

Perceptive Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-229,807	Closed	-$8.88M	–	141
2021 Q4	$8.88M	Sell	229,807 -163,806	-42%	-$7.14M	0.14%	101
2021 Q3	$21.3M	Sell	393,613 -349,086	-47%	-$16.4M	0.31%	67
2021 Q2	$24.8M	Buy	+742,699	New	+$20.4M	0.32%	77
2020 Q4	–	Sell	-49,751	Closed	-$738K	–	146
2020 Q3	$738K	Buy	+49,751	New	+$583K	0.01%	119
2017 Q2	–	Sell	-465	Closed	-$25K	–	142
2017 Q1	$25K	Buy	+465	New	+$24.2K	﹤0.01%	141
2016 Q3	–	Sell	-4,742	Closed	-$312K	–	197
2016 Q2	$312K	Buy	+4,742	New	+$301K	0.02%	139
2015 Q1	–	Sell	-6,667	Closed	-$1.82M	–	160
2014 Q4	$1.82M	Buy	+6,667	New	+$1.66M	0.15%	91

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Perceptive Advisors's CLDX Position: Q1 2022 in Review

Perceptive Advisors sold out of Celldex Therapeutics (CLDX) in Q1 2022, closing a stake of 229,807 shares — an estimated $8.88M sold.

Perceptive Advisors first reported a position in CLDX in Q4 2014 and held it in 7 quarters. The position peaked at $24.8M in Q2 2021. 168 funds tracked by Wall St. Rank hold CLDX as of Q1 2022.

Perceptive Advisors reported no remaining Celldex Therapeutics position as of Q1 2022 after selling out during the quarter.
Perceptive Advisors sold 229,807 Celldex Therapeutics shares in Q1 2022, an estimated $8.88M.
Perceptive Advisors first reported a position in Celldex Therapeutics in Q4 2014 and held it in 7 quarters.
Perceptive Advisors's Celldex Therapeutics position peaked at $24.8M in Q2 2021.
168 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2022.

Based on Perceptive Advisors's 13F filing for Q1 2022, filed 16 May 2022.